Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 892 of 6351
-
New pill shows promise against childhood brain tumor
Disease control Recruiting nowThe current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Phase 2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo aims to keep leukemia in check longer
Disease control OngoingA study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope: pill may stop remaining lung spots from becoming cancer
Disease control Recruiting nowThis study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can a daily pill keep leftover lung spots from turning into cancer?
Disease control Recruiting nowThis is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a common diabetes drug save heart failure patients?
Disease control Recruiting nowThe EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high r…
Phase 3 • Sponsor: Juntendo University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cocktail of drugs and radiation takes on tough lung cancer
Disease control CompletedThis is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).
Phase 2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Crohn's patients may avoid unnecessary drugs after surgery, new study suggests
Prevention Recruiting nowWith this prospective, randomized, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative endoscopic recurrence at week 86 compared to systematic prop…
Phase 4 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Peanut allergy pill shows promise in early trial
Disease control CompletedThis clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Phase 1/2 • Sponsor: ALK-Abelló A/S • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
100,000 babies to get DNA screening for hidden genetic diseases
Knowledge-focused Recruiting nowThe goal of this study is to learn how genomic sequencing technology can be used to effectively expand the conditions screened on newborn screening. Newborn screening ensures equity and allows all babies to have the same chance at the healthiest life. Families will be invited to …
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:52 UTC
-
New drug aims to tame rare blood disorder flares
Disease control Recruiting nowThis is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Hope for Alzheimer's agitation: new drug shows promise in major trial
Symptom relief CompletedThis trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Weight-Loss drug semaglutide tested as heart failure treatment
Symptom relief CompletedThe purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Phase 4 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowTROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for tough lymphoma: sonrotoclax trial underway
Disease control OngoingThe study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy …
Phase 1/2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 26, 2026 14:39 UTC
-
Brain tumor trial combines radiation with targeted drugs and immunotherapy
Disease control OngoingThis study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug DYNE-101 aims to ease muscle stiffness in rare disease
Disease control Recruiting nowThe primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled…
Phase 1/2 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy boost before surgery shows promise against head and neck cancer
Disease control OngoingThe objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (Toripalimab combined …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Brain zaps show promise against suicidal thoughts in depression
Symptom relief Recruiting nowThis is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm. In this proposed study, the investigators will evaluate th…
Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New combo attack on returning prostate cancer shows promise in early trial
Disease control OngoingThis phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment (oligorecurrent). Radioactive drugs, such as 177-Lutet…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Brain cancer breakthrough? new CAR T-Cell trial hopes to tame glioblastoma
Disease control Recruiting nowThe purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC